Adherence to asthma and COPD therapies in low- and middle-income countries: a narrative review [0.03%]
发展中国家哮喘和慢阻肺治疗依从性的叙事综述
Vaibhav Gaur,Alessandra Sorano,Himanshu Sankrityayan et al.
Vaibhav Gaur et al.
Introduction: In low-income and middle-income countries (LIMCs), defined based on the World Bank classification, non-adherence to respiratory therapies contributes to increasing mortality and morbidity due to chronic resp...
Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair [0.03%]
分层加速术后康复路径在腹壁疝修补术中应用及实施效果研究
James Espeleta,Sunitha Singh,Ethan Augustine et al.
James Espeleta et al.
Introduction: Enhanced recovery after surgery (ERAS) pathways are widely adopted in both major and minimally invasive surgeries. However, ERAS pathway implementation in ventral hernia repair (VHR) surgery remains an area ...
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and shiga prefecture [0.03%]
日本66-84岁成人接种20价肺炎球菌结合疫苗的卫生和经济影响及评估其在京都市的应用效果
Tomoyuki Suzuki,Yoko Hirano,Kazumasa Kamei et al.
Tomoyuki Suzuki et al.
Background: The Japanese National Immunization Program against pneumococcal disease (PD) includes 23-valent pneumococcal polysaccharide vaccine (PPSV23) but does not provide vaccination for adults aged ≥66 years. We eval...
Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation [0.03%]
奥希替尼与达可替尼作为EGFR突变阳性晚期非小细胞肺癌一线治疗的成本效用分析
Lili Su,Xiangyu Zhang,Mengrong Li et al.
Lili Su et al.
Objective: To evaluate the cost-effectiveness of osimertinib compared to dacomitinib for advanced non-small cell lung cancer with EGFR mutation from the perspective of China's health system. ...
Determinants of cancer drug prices in Germany and France: a multiple regression analysis [0.03%]
德国和法国抗癌药物价格决定因素：多元回归分析
Nethra Subramanian,Aadhav Subramanian
Nethra Subramanian
Background: Higher prices for drugs targeting rarer cancers may be justified, but the extent remains uncertain. This research analyses the determinants of cancer drug prices in Germany and France. ...
Cost-effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine in Indian adults aged ≥50 years [0.03%]
印度50岁以上成人接种13价肺炎球菌多糖结合疫苗的成本效益分析
Namrata Kulkarni,Ahuva Averin,Santosh Taur et al.
Namrata Kulkarni et al.
Objectives: Lacking national policy for adult pneumococcal vaccination, local Indian guidelines recommend 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide v...
The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama [0.03%]
巴拿马预防儿童呼吸道合胞病毒新免疫策略的潜在公共健康影响
Xavier Sáez-Llorens,Pieralessandro Lasalvia,Paola Jaramillo et al.
Xavier Sáez-Llorens et al.
Objective: New prophylaxis to reduce the burden of respiratory syncytial virus (RSV) disease are available, including a long-acting monoclonal antibody (nirsevimab) and maternal immunization with an RSV prefusion F protei...
Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit [0.03%]
心血管-肾脏和代谢疾病患者的临床及经济效益结局：意大利单个卫生区的现实世界分析
Valentina Perrone,Domenica Daniela Ancona,Marco Gnesi et al.
Valentina Perrone et al.
Background: This single-center real-world analysis describes the epidemiology, demographic and clinical characteristics, mortality, and therapeutic-care management of patients grouped by the presence of seven cardiorenal ...
Exploring the psychometric properties of the fatigue severity scale: results from a systematic review and reliability meta-analysis [0.03%]
疲劳严重程度量表的测量属性：系统评价和可靠度meta分析结果
Ilaria Ruotolo,Andrea Carenza,Giovanni Sellitto et al.
Ilaria Ruotolo et al.
Introduction: Fatigue is a multifactorial phenomenon that affects individuals across several conditions. Fatigue Severity Scale (FSS) is a widely used questionnaire to measure perceived fatigue. This systematic review aim...
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece [0.03%]
希腊转移性去势抵抗性前列腺癌患者的医疗资源利用及其相关成本
E Bournakis,A Bournakis,D V Zolota et al.
E Bournakis et al.
Background: Prostate cancer is a leading cause of cancer death among men. Metastatic castration-resistant prostate cancer (mCRPC) treatment has changed dramatically since the introduction of novel hormonal agents (NHAs); ...